Drug Name |
Ropinirole hydrochloride |
Drug ID |
BADD_D01967 |
Description |
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547].
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. |
Indications and Usage |
For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome. |
Marketing Status |
Prescription; Discontinued |
ATC Code |
N04BC04 |
DrugBank ID |
DB00268
|
KEGG ID |
D00784
|
MeSH ID |
C046649
|
PubChem ID |
68727
|
TTD Drug ID |
D0R9EQ
|
NDC Product Code |
46708-034; 63629-7152; 62332-031; 46708-036; 50090-4810; 43547-268; 0904-6373; 43547-600; 43547-269; 46708-031; 62332-035; 65096-0102; 54752-0005; 46708-032; 62332-034; 62332-033; 65841-714; 0615-8191; 0615-8190; 71335-1626; 62332-032; 61919-564; 65841-716; 46708-030; 62332-030; 43547-601; 65841-713; 0904-6374; 50090-3304; 43547-596; 0615-8188; 70518-2476; 43547-597; 55111-091; 60687-588; 63629-4798; 43547-595; 62147-0015; 60687-577; 46708-869; 43547-271; 61187-008; 58032-0133; 43547-270; 71335-0727; 43547-274; 43547-599; 0615-8189; 66039-853; 43547-273; 55154-7888; 50090-4348; 71335-0587; 62147-0008; 71335-1434; 65841-715; 46708-035; 51655-360; 43547-598; 65841-712; 62332-036; 55154-7633; 71335-0829; 65841-718; 65841-717; 43547-272; 64220-121; 46708-033 |
Synonyms |
ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride |